Clinical Trial Detail

NCT ID NCT02023333
Title Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

colorectal adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.